
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Holdings Inc. is projected to see significant growth in Wakix sales, anticipated to increase from approximately $160 million in 2020 to over $700 million by 2024, driven by the drug's safety and convenience advantage. The company has a strong pipeline of orphan drug candidates in various stages of development, including pitolisant-GR, which aims to enhance patient adherence by removing the need for dose titration. Additionally, ongoing and upcoming registrational trials, combined with a robust balance sheet to fund research and development, position Harmony as a compelling growth story within the neurology sector.
Bears say
Harmony Biosciences Holdings Inc. faces significant challenges that contribute to a negative outlook on its stock. The failure of the pivotal Phase 3 RECONNECT trial for ZYN002, attributed to a higher-than-expected placebo response, raises concerns about the viability of its drug pipeline and underscores potential hurdles in future clinical trials. Additionally, increasing competition in the sodium oxybate market and the possibility of slowed patient acquisition for WAKIX further complicate the company's growth prospects.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares